Site search

Clear filter
2860 results for '' found
Evaluation of Safety and Feasibility of the Tioga TMVR System for Treatment of Mitral Regurgitation (NCT06038838)
Evaluation of Safety and Feasibility of the Tioga TMVR System for Treatment of Mitral Regurgitation (NCT06038838)
/
Impact of Total Arterial Revascularisation in Coronary Artery Surgery on Angiographic and Clinical Outcomes (ACTRN12623000864628)
Impact of Total Arterial Revascularisation in Coronary Artery Surgery on Angiographic and Clinical Outcomes (ACTRN12623000864628)
/
A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients with Normalized Cancer Therapy Related Cardiac Dysfunction: The STOP-MED CTRCD Trial (NCT061
A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients with Normalized Cancer Therapy Related Cardiac Dysfunction: The STOP-MED CTRCD Trial (NCT061
/
The SMART-AF study (ACTRN12625000481471)
The SMART-AF study (ACTRN12625000481471)
/
The Alison Project: A randomised double-blind placebo controlled investigation of adjunctive memantine in the treatment of symptoms of complex trauma disorder (also known as borderline personalit
The Alison Project: A randomised double-blind placebo controlled investigation of adjunctive memantine in the treatment of symptoms of complex trauma disorder (also known as borderline personalit
/
Determine whether analgesia for patients undergoing minimally invasive major abdominal surgery using Intrathecal Morphine with local anaesthetic affects quality of recovery. The AIM Study (ACTRN1
/
The TELO-SCOPE Study: Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis? (NCT04638517)
/
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced M
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced M
/
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements (NCT05727176)
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements (NCT05727176)
/
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome o
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome o
/
19 20 21 22 23